Pharmaceuticals
Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting
BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Ass...
2021-09-09 15:00
2248
Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility
SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...
2021-09-09 11:40
3498
WCLC 2021 | Mini Oral - Ascentage Pharma Announces Latest Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) Combined with Osimertinib in Patients with EGFR TKI-Resistant Non-Small Cell Lung Cancer
SUZHOU, China, and ROCKVILLE, MD., Sept 9, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today reported the Phase Ib results of the dual Bcl-2/Bcl-xL inhi...
2021-09-09 08:26
5421
CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC WCLC 2021
SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced that efficacy and safety data from a...
2021-09-09 08:00
3350
HaemaLogiX raises $10 million to advance multiple myeloma treatments
* HaemaLogiX completes a fully subscribed $10 million share placement and welcomes Platinum Asset Management as core new institutional investor within its Platinum International Health Care Fund * Funding underpins HaemaLogiX's drug development pipeline, targeting multiple myeloma - the sec...
2021-09-09 05:00
2032
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met
SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-8...
2021-09-08 22:13
4025
Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets
SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Huadong Medicine (SZ.000963) and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that the companies have entered into a co-development partnership to accelerate the discovery of brea...
2021-09-08 20:08
2904
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...
2021-09-08 19:00
3765
Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets Granted Drug Certificate
SHIJIAZHUANG, China, Sept. 8, 2021 /PRNewswire/ -- Yiling Pharmaceutical recently announced that its newly-developed drug Yishen Yangxin Anshen Tablet had been granted official drug certificate byChina's National Medical Products Administration (NMPA). With the functions of reinforcing kidney, n...
2021-09-08 12:28
2304
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
NORTH BRUNSWICK, New Jersey and HANGZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple ...
2021-09-08 11:04
2063
Innovent Announces First Patient with Type 2 Diabetes Dosed in a Phase 2 Clinical Trial of IBI362 (a GLP-1R and Glucagon Receptor Dual Agonist) in China
SAN FRANCISCO and SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-09-08 08:00
7394
Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
DURHAM, N.C. and BEIJING, Sept. 7, 2021 /PRNewswire/ -- Brii Biosciences
2021-09-07 19:04
4316
RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
- COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive process which occurs in patients with chronic kidney disease (CKD) and can ultimately lead to ...
2021-09-07 19:00
2541
RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
- Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients aged ≥ 65 years - Analysis of Movantik effects on rapid and sustained improvement of both spontaneous and complete spontaneous bowel movements in the Movantik group vs. placeb...
2021-09-07 18:00
2748
Jubilant Biosys Limited announces the appointment of Mr. Giuliano Perfetti as Chief Executive Officer
BENGALURU, India, Sept. 7, 2021 /PRNewswire/ -- Today, Jubilant Biosys Limited
announced the appointment ofGiuliano Perfetti as its Chief Executive Officer.
2021-09-07 16:11
3565
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
* The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally * Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, g...
2021-09-06 19:03
4453
GenScript ProBio Enters into Agreement with SYNIMMUNE for Manufacturing of their Innovative Antibody Drug
NANJING, China, Sept. 6, 2021 /PRNewswire/ -- GenScript ProBio is delighted to announce the signing of a manufacturing service agreement for Synimmune's innovative FLYSYN antibody project for clinical Phase II production. FLYSYN is a fms-like tyrosine kinase 3 (FLT3) specific antibody for the ...
2021-09-06 16:00
2615
Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...
2021-09-06 13:44
3772
Kintor Pharma Included in Hong Kong Stock Connect Program
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hong Kong Stock Conn...
2021-09-06 11:30
3695
CStone Pharmaceuticals Included in the Hong Kong Stock Connect
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has been...
2021-09-06 11:30
3637
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9273
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7751